Order-of-magnitude gap: the company is already serving a demand source whose scale dwarfs its own current business
The model's full reasoning — Q3 2018 call → NOWe need to determine if management describes a mismatch of scale between the company and the demand it is already serving. The key is: the company is already inside a large flow of activity, and management explicitly draws the size contrast, treating it as the point. Looking at the transcript: The company is Surmodics, a medical device company. They have a deal with Abbott for SurVeil Drug-Coated Balloon. They receive revenue from Abbott. They also have other products. The question is whether management describes a situation where the company is already serving something enormous relative to its own size, and management highlights that disproportion. In the transcript, management talks about the Abbott deal, the SurVeil DCB, and the TRANSCEND trial. They mention revenue from Abbott. They also talk about the thrombectomy market being $400 million. But is the company already inside that market? They acquired Embolitech technology, but it's in development, not yet commercial. So that's prospective. The Abbott deal: They are supplying SurVeil to Abbott, and Abbott has worldwide commercialization rights. The company is already earning revenue from Abbott. But does management draw a contrast between the company's size and the scale of what it's serving? They mention the market for peripheral artery disease, but they don't explicitly say "this is a huge market and we are tiny, and we are already in it." They talk about the partnership with Abbott, but they don't emphasize the disproportion. The question asks: "does management convey that the company is currently supplying, serving, or participating in something whose size, spending, volume, or population is ENORMOUS RELATIVE TO THE COMPANY'S OWN CURRENT BUSINESS, such that even a modest further share of it would make the company several times bigger than it is today?" Management does mention the $400 million thrombectomy market, but that's for a product still in development. They also mention the peripheral artery disease market, but they don't quantify it relative to their own size. They talk about the Abbott deal, but they don't say "we are a small company and this is a huge opportunity we are already part of." They do mention that they are supplying to Abbott, but they don't draw the contrast explicitly. The essence is that management must make the disproportion explicit or unmistakable.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| GDRX | GoodRx Holdings, Inc. | Q2 2022 | 2022-08-08 | F |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| IRTC | iRhythm Technologies, Inc. | Q1 2022 | 2022-05-07 | C+ |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| RELY | Remitly Global, Inc. | Q4 2021 | 2022-03-02 | B |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| HSTM | HealthStream, Inc. | Q3 2017 | 2017-10-24 | C |
HROW · Q4 2021 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...YES The transcript shows management describing Harrow as already inside the large cataract surgery market (4.5–6 million procedures annually) with real, present-tense participation: thousands of customer relationships, shipping north of two million sterile ophthalmic units last year, and touching roughly one million cataract surgeries. They explicitly contrast this scale against 2021 revenues of $72.5 million, noting that even a modest share of the pass-through-eligible market (1 million procedures × premium pricing) would produce “a big number” and drive revenues “more than double” in the near term. They treat the current business as only the “earliest sliver” of what they are already positioned inside, with the binding question being how much of the existing flow they can capture rather than whether the flow exists. This meets both criteria. The answer is YES. The transcript shows management describing Harrow as already inside the large cataract surgery market (4.
WRBY · Q1 2024 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...YES The transcript explicitly states that the company is already inside the optical industry with real business (245 stores serving customers, 83% of stores offering exams, 2.36 million active customers, and growing revenue from glasses, contacts, and exams). Management then draws the size contrast directly, noting that even the longer 900-store target "would still represent a small fraction of the 45,000 optical shops in the U.S." and that over 50% of major metro areas have only one store.
HSTM · Q3 2017 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...**YES** Management describes the company already being inside a much larger flow of activity (the 80 million-person healthcare workforce, of which 4.6 million are in post-acute settings) and explicitly treats the scale mismatch as the central point. They note their strong sales team is already a “steady contributor” to 4.